Search Medical Condition
Please enter condition
Please choose location from dropdown

Uterine Disorders Clinical Trials

A listing of Uterine Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (562) clinical trials

The primary objective of this study is to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Phase

Consider a research study for uterine fibroids. The Asteroid Studies are research studies evaluating the safety and effectiveness of an investigational oral medication for uterine fibroids.

Phase N/A

The purpose of this study is to determine the safety and effectiveness of elagolix compared to placebo in reducing heavy menstrual bleeding associated with uterine fibroids. Subjects will be randomly assigned to take elagolix or placebo. Some subjects will also be randomly assigned to receive elagolix in combination with add-back ...

Phase N/A

To evaluate the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy in the management of endometriosis-associated pain (EAP) in premenopausal women.

Phase

To study the safety and efficacy of Relugolix administered with and without low-dose estradiol and norethindrone acetate in women with endometriosis-associated pain

Phase N/A

To determine the benefit of relugolix 40 mg once daily co-administered with low dose estradiol and norethindrone acetate compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids

Phase N/A

To demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 

Phase N/A

To assess the safety and efficacy of elagolix 300 mg BID in combination with E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg QD) compared to placebo at 1 year in reducing heavy menstrual bleeding associated with uterine fibroids in premenopausal women 

Phase N/A